HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Glassock, R. J. Articles by Barberato, S. H. Search for Related Content PubMed PubMed Citation Articles by Glassock, R. J. Articles by Barberato, S. H.

Left Ventricular Mass in Chronic Kidney Disease and ESRD

Richard J. Glassock^*, Roberto Pecoits-Filho, and Silvio H. Barberato

^* The David Geffen School of Medicine at UCLA, Los Angeles, California; and
Center for Health and Biological Sciences, Pontificia Universidade Catolica do Parana, Curitiba, Brazil

Correspondence: Dr. Richard J. Glassock, 8 Bethany, Laguna Niguel, CA 92677. Phone: (949) 388-8885; Fax: (949) 388-8882; E-mail: Glassock{at}cox.net

Chronic kidney disease (CKD) and ESRD, treated with conventional hemo- or peritoneal dialysis are both associated with a high prevalence of an increase in left ventricular mass (left ventricular hypertrophy [LVH]), intermyocardial cell fibrosis, and capillary loss. Cardiac magnetic resonance imaging is the best way to detect and quantify these abnormalities, but M-Mode and 2-D echocardiography can also be used if one recognizes their pitfalls. The mechanisms underlying these abnormalities in CKD and ESRD are diverse but involve afterload (arterial pressure and compliance), preload (intravascular volume and anemia), and a wide variety of afterload/preload independent factors. The hemodynamic, metabolic, cellular, and molecular mediators of myocardial hypertrophy, fibrosis, apoptosis, and capillary degeneration are increasingly well understood. These abnormalities predispose to sudden cardiac death, most likely by promotion of electrical instability and re-entry arrhythmias and congestive heart failure. Current treatment modalities for CKD and ESRD, including thrice weekly conventional hemodialysis and peritoneal dialysis and metabolic and anemia management regimens, do not adequately prevent or correct these abnormalities. A new paradigm of therapy for CKD and ESRD that places prevention and reversal of LVH and cardiac fibrosis as a high priority is needed. This will require novel approaches to management and controlled interventional trials to provide evidence to fuel the transition from old to new treatment strategies. In the meantime, key management principles designed to ameliorate LVH and its complications should become a routine part of the care of the patients with CKD and ESRD.

This article has been cited by other articles:

				E. P. McQuarrie, R. K. Patel, P. B. Mark, C. Delles, J. Connell, H. J. Dargie, T. Steedman, and A. G. Jardine Association between proteinuria and left ventricular mass index: a cardiac MRI study in patients with chronic kidney disease Nephrol. Dial. Transplant., July 12, 2010; (2010) gfq418v1. [Abstract] [Full Text] [PDF]